This $15 Billion Operational Beat Just Rewrote the Entire Bear Thesis for AbbVie

The post This $15 Billion Operational Beat Just Rewrote the Entire Bear Thesis for AbbVie appeared first on 24/7 Wall St..

• AbbVie (ABBV) posted Q1 revenue of $15.002B (beating consensus by $284M) with a 65.4% free cash flow payout ratio and 13-year dividend streak, supporting its 2.98% yield.
• Skyrizi and Rinvoq are replacing low-margin Humira faster than expected, with strong guidance raised to $14.28 adjusted EPS supporting AbbVie's dividend sustainability.
• Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and AbbVie didn't make the cut. Grab the names FREE today.

For income investors weighing biopharma exposure, the dividend question on AbbVie (NYSE:ABBV) just got a lot easier to answer. The company posted $15.002 billion in Q1 2026 revenue, beating consensus by $284 million, and management raised full-year adjusted EPS guidance to $14.08 to $14.28. With the stock yielding nearly 3%, the question is whether the payout can survive the post-Humira chapter.

Dividend Snapshot

Metric	Value
Annual Dividend	$6.92 per share
Dividend Yield	2.98%
Consecutive Years of Increases	13 years
Most Recent Increase	5.5% (October 2025)
Aristocrat Status	Yes (with Abbott legacy)

Free Cash Flow Buries the Bear Thesis

AbbVie generated $17.816 billion in free cash flow in 2025 against $11.657 billion in dividends paid. That is a 65.4% FCF payout ratio, comfortably inside the healthy zone. On adjusted earnings of $10.00 for FY 2025, the $6.92 dividend works out to roughly 69%, also manageable.

Metric	TTM Value	Assessment
Adjusted Earnings Payout	~69%	Healthy
FCF Payout Ratio	65.4%	Healthy
Operating Cash Flow Coverage	1.63x	Adequate

The thesis is straightforward: high-margin biologics and a defensive aesthetics portfolio are replacing low-margin Humira faster than skeptics expected. Skyrizi grew 30.9% to $4.483 billion and Rinvoq grew 23.3% to $2.119 billion in Q1 alone.

Leverage Is the Only Real Knock

Metric	Value	Assessment
Net Debt/EBITDA	2.26x	Manageable
Interest Coverage	6.94x	Strong
Shareholders’ Equity	Negative (Allergan legacy)	Accounting artifact

The negative book value reflects the Allergan goodwill writedown, an accounting artifact rather than a cash flow problem. 2025 financing cash flow of -$12.724 billion shows aggressive deleveraging.

A 13-Year Streak That Keeps Compounding

The quarterly dividend has marched from $0.40 in 2013 to $1.73 in 2026. CFO Scott Reents told investors on the Q1 call, “AbbVie continues to deliver outstanding results and our financial health remains very strong.” CEO Rob Michael added that capital priorities include “returning capital to shareholders through our strong and growing dividend.”

My Verdict: Safe

Dividend Safety Rating: Safe. A 65% FCF payout, 6.94x interest coverage, and a guidance raise to $14.28 adjusted EPS at the high end leave plenty of room. The setup looks durable for retirement income investors if Skyrizi and Rinvoq keep tracking toward management’s $21.6 billion and $10.2 billion 2026 targets. Investors should watch for FCF coverage dropping below 1.3x or the 2028 patent cliff narrative pushing leverage back above 3x EBITDA. For now, this dividend looks built for retirees.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and AbbVie didn’t make the cut. Grab the names FREE today.

The post This $15 Billion Operational Beat Just Rewrote the Entire Bear Thesis for AbbVie appeared first on 24/7 Wall St..